Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma
British Journal of Haematology · 2026-11 · 209 (5) · 2321-2325
DOI: 10.1111/bjh.70775 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 27.08.2026. Verfasst von Edvan Q Crusoé und 20 weiteren Autor:innen. Beteiligte Einrichtung: Rede D'Or Oncologia, Salvador, Brazil. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rede D'Or Oncologia, Salvador, Brazil.
- Universidade Federal da Bahia, Salvador, Brazil.
- Clinica Hematológica, Belo Horizonte, Brazil.
- Faculdade de Medicina de Campos, Campos dos Goytacazes, Brazil.
- A.C. Camargo Cancer Center-Rua Prof. Antônio Prudente, São Paulo, Brazil.
- Hospital Italiano, Ciudad Autónoma de Buenos Aires, Argentina.
ORCID-Profile: Edvan Q Crusoé, João Tadeu D Souto Filho, Milton A F Aranha, Abel Costa, Abrahao Hallack, Juliana S Lima, Jorge P Vaz, Rosane Bittencourt, Ederson R Mattos, Vania Hungria
Zitieren
APA
Crusoé, E. Q., Ribeiro, G., Souto Filho, J. T. D., Schmidt Filho, J., Schutz, N., Aranha, M. A. F., Costa, A., Hallack, A., Pericole, F. V., Lima, J. S., Gusmão, B., Ribeiro, E. F. O., Vaz, J. P., Bittencourt, R., Cunha, R., Ovigli, D., Berg, L., Mattos, E. R., Maiolino, A., …, & GBRAM (2026). Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. British Journal of Haematology, 209(5), 2321-2325. https://doi.org/10.1111/bjh.70775
Vancouver
Crusoé EQ, Ribeiro G, Souto Filho JTD, Schmidt Filho J, Schutz N, Aranha MAF, et al. Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. British Journal of Haematology. 2026;209(5):2321-2325. doi:10.1111/bjh.70775
BibTeX
@article{Cruso2026,
author = {Crusoé, Edvan Q and Ribeiro, Glaciano and Souto Filho, João Tadeu D and Schmidt Filho, Jayr and Schutz, Natalia and Aranha, Milton A F and Costa, Abel and Hallack, Abrahao and Pericole, Fernando V and Lima, Juliana S and Gusmão, Breno and Ribeiro, Eduardo Flávio O and Vaz, Jorge P and Bittencourt, Rosane and Cunha, Rafael and Ovigli, Danielle and Berg, Luiza and Mattos, Ederson R and Maiolino, Angelo and Hungria, Vania and GBRAM, GBRAM},
title = {Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2321--2325},
doi = {10.1111/bjh.70775}
}
EUVIMED